Emerging Business Models in the Pharmaceutical Industries ...

Introduction
Pharma Industry Overview
The pharma industry is affected by the dynamic shifts in the
market. New revenue models are resulting from activities such
as parallel trade, the generic vs. patent fight, mergers and
acquisitions (M&A), in-licensing and out-licensing, and the
choice between semi block buster and block buster. The shift
from chemical-based small molecules to biology-based large
molecules like antibodies and protein has also created new
opportunities in the industry.
Distinct Positioning for Pharma Companies
Pharma companies are distinctly positioning themselves on the
basis of their capabilities, banking on their R&D strength,
marketing network, and capitalisation to decide their portfolio.
Smaller Pharma companies are Consolidating forming a
“Supernet” of Pharma companies complementing their
capabilities to each other. The Big Pharma companies are
consolidating to lead the league as “Super Pharmas”.
Companies have to choose between pharma, biotech and their
respective generic models.
Niche players are tending towards M&A to safeguard their
focus, and achieve business goals. Pharma companies are
positioning themselves as biotech or pharma on the stock
market. Incorrect positioning of these companies can impact
their capitalisation, which remains the key to growth.
Strategic Analysis of the Pharma Market, Future Revenue Models and Key Players 7